AIM ImmunoTech Total Revenue

The latest total revenue for AIM is $95K as of June 2026. That compares with $120K in the prior-year period — down 21.5% year over year. That is below the Healthcare sector average of $110B. Investors often review this figure alongside AIM ImmunoTech's historical trend and sector peers before judging valuation or financial health.

Over the past year, AIM's total revenue moved from $120K to $95K — a 21.5% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in AIM ImmunoTech's operating scale or balance-sheet position.

Against Healthcare companies, AIM currently prints $95K for total revenue, while the sector average sits near $110B. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at AIM ImmunoTech's growth, margins, and balance sheet.

A total revenue figure of $95K for AIM is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $110B. Explore the charts below for those layers of context.

After noting AIM's total revenue ($95K), review year-over-year change from $120K, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.